← 홈

다발성 골수종

24개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 24개
ADCBiologicPalleos Healthcare GmbHvedotin, vinblastine, and d…Phase 2

Adriamycin (Adriamycin)

Multiple Myeloma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 95%임상시험 70상태 ACTIVE
AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
ADCBiologicCelyad Oncology SAPhase 2

Endoxan (Endoxan)

Relapse/Refractory Multiple Myeloma · Lymphoma, T-Cell, Peripheral

#LymphomaT-CellPeripheral#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 62상태 ACTIVE
AntibodyBristol Myers Squibbvedotin in patients with re…Phase 2

nivolumab (Opdivo, Nivolumab and Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 62상태 RECRUITING
ADCBiologicAmerican Society of Clinical On…Phase 2

Dabrafenib plus Trametinib (Dabrafenib plus Trametinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 79.5%임상시험 32상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
ADCBiologicstaleAmerican Society of Clinical On…Phase 2

Vemurafenib and Cobimetinib (Vemurafenib and Cobimetinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 65%임상시험 30상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Daratumumab/rHuPH20)

Multiple Myeloma; Non-Hodgkin Lymphoma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+3
효능 ORR 39.4%임상시험 24상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 2상태 ACTIVE
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleKang YUPreclinical

CAR-BCMA T cell (CAR-BCMA T cell)

B Cell Lymphoma; B Cell Leukemia · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleAffiliated Hospital to Academy …Phase 1

CAR19BCMA-T cells (CAR19BCMA-T cells)

Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR T cells (CD19/CD20/BCMA CAR T cells)

Non-Hodgkin Lymphoma, B-cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING

1 / 2 페이지

← 이전다음 →